Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 27.7% from a year ago
Other current assets stood at $2.38M at the end of Q1 FY2026, down 27.7% from a year earlier and up 28.0% from the prior quarter. Over 3 fiscal years it compounded at +198.4% a year.
Context
- Other current assets amounted to 2.4% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -27.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.86M USD
- Year-over-year change
- +1061.9%
- 3-year CAGR
- +198.4%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.86M | +1061.9% |
| FY2024 | 2024-12-31 | 160K | +26.0% |
| FY2023 | 2023-12-31 | 127K | +81.4% |
| FY2022 | 2022-12-31 | 70K | — |
Other Current Assets vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 other current assets of $2.38M is the 8th highest of the 11 companies compared; the peer median is $3.02M.
- Its year-over-year change of -27.7% is the 7th highest of 10, against a peer median of +5.7%.
- Other current assets amounts to 2.4% of total assets for AARD, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.83M | +10919.4% | +74.6% | 6.8% | |
| Mar 2026 | $6.81M | -23.1% | — | 2.2% | |
| Mar 2026 | $5.56M | +35.7% | +163.2% | 2.4% | |
| Mar 2026 | $3.18M | -34.1% | -8.1% | 1.4% | |
| Mar 2026 | $3.08M | -52.1% | -5.6% | 4.8% | |
| Mar 2026 | $2.96M | +6.2% | — | 1.7% | |
| Mar 2026 | $2.39M | +5.7% | +37.6% | 1.6% | |
| Mar 2026 | $2.38M | -27.7% | +198.4% | 2.4% | |
ZURAZura Bio Limited | Mar 2026 | $1.41M | +25.6% | +148.4% | 0.6% |
| Mar 2026 | $25K | -98.0% | +3.0% | 0.0% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $8.5K | — | — | 0.0% |
| Peer median (excluding AARD) | $3.02M | +5.7% | +37.6% | 1.6% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.